March 30 – April 6, 2026
🔬 THIS WEEK'S BIG IDEA
Aging Is Not a Defect — It's a Loss of Coordination
The most talked-about story in longevity science this week is a conceptual one. Researchers gathering at the 2nd World Congress on Targeting Longevity (Berlin, April 8–9) are challenging a core assumption that has guided the field for decades: that aging is caused by a collection of discrete molecular defects to be fixed one by one.
The emerging view? Aging is better understood as a progressive loss of biological coordination — a systems-level failure in which mitochondria, the gut microbiome, the immune system, and metabolic signalling gradually stop communicating effectively.
Speakers including Nancy M. Bonini, João Pedro de Magalhães, Viktor Korolchuk, and João F. Passos are calling for a shift toward "resilience engineering" — stabilising biological networks rather than targeting single pathways. This has big implications for how therapies are developed and funded.
"The next breakthrough may not be a molecule. It may be a new way of understanding how biological systems communicate, adapt, and sometimes lose balance."
📰 RESEARCH & NEWS HIGHLIGHTS
1. AI Pours Into Longevity Drug Discovery
On March 29, Eli Lilly committed $2.75 billion to Insilico Medicine for AI-discovered drug candidates. Insilico has 28 compounds in its pipeline, with nearly half already in clinical trials — and their first compound went from target identification to Phase I in under 30 months (traditional pharma typically takes 4–6 years).
The broader picture is striking: as of early 2026, 173 AI-discovered drug programs are now in clinical development — 94 in Phase I, 56 in Phase II, and 15 in Phase III. AI-discovered compounds are showing Phase I success rates of 80–90%, compared to the historical norm of 40–65%.
Other notable deals this week: Gero signed a research agreement with Chugai Pharmaceutical for AI-discovered therapies targeting age-related diseases, and Biophytis presented its AI longevity platform at NVIDIA GTC 2026.
2. The Thymus: A Surprisingly Powerful Longevity Organ
Long considered dormant after childhood, the thymus is getting a serious scientific rehabilitation. A major study published this week in Nature used a deep learning framework to quantify thymic health from routine CT scans across two large cohorts — including 25,031 participants in the National Lung Screening Trial.
The results were striking: people with higher thymic health scores had roughly 50% lower all-cause mortality risk, 63% lower cardiovascular death risk, and 36% lower lung cancer risk over 12 years. Thymic health also correlated with systemic inflammation and metabolic health — and was tied to modifiable factors like smoking, obesity, and physical activity.
3. New Biological Age Clocks Published in Nature Aging
Researchers this week presented two new tools for measuring biological age: EMRAge (built from electronic medical records) and OMICmAge (a multi-omic signal layered on DNA methylation). Both show strong associations with disease risk and mortality in validation cohorts — and represent a move toward biological age measures that are practical in clinical settings.
Separately, a transformer-based analysis of electronic health records identified five distinct subtypes of Alzheimer's and Parkinson's disease — each with unique trajectories, comorbidities, and genetic profiles. This kind of personalised subtyping could transform both research design and treatment development.
4. cGAS-STING: Rewiring Aging's Inflammatory Circuit
A flurry of new research is targeting the cGAS-STING pathway — one of the key mechanisms driving chronic inflammation in aging. As cells age, DNA leaks from the nucleus and mitochondria, triggering cGAS (a sensor evolved to detect viral invaders), which then fires sustained inflammatory signals via STING. The result is the low-grade, whole-body inflammation sometimes called "inflammaging."
New 2026 work published in PNAS and Frontiers in Cell and Developmental Biology is moving beyond simply blocking the pathway to a more nuanced approach called "signal reprogramming" — using TLR2 agonists and other tools to redirect the pathway's output toward tissue repair rather than destruction. Separately, a Nature study from 2023 confirming cGAS-STING's central role in neurodegeneration continues to shape this growing research area.
📖 PNAS: A noncanonical cGAS–STING pathway drives cellular and organismal aging | Frontiers: cGAS-STING in aging ovary
5. Microplastics: An Emerging Aging Accelerant
A new review published in Pathogens this week — Micro- and Nanoplastics Exposure Across the Lifespan: One Health Implications for Aging and Longevity — makes a compelling case that micro- and nanoplastic (MNP) exposure is a meaningful driver of biological aging, particularly for older adults who have accumulated decades of exposure.
Experimental data consistently shows MNP exposure triggers oxidative stress, chronic inflammation, mitochondrial dysfunction, and cellular senescence — the same mechanisms central to aging. Smaller particles and higher concentrations produce the most pronounced effects. The authors call for urgent research into chronic, low-dose exposure scenarios and their long-term health impact.
🎙️ PODCAST ROUNDUP
🟢 Huberman Lab
Episode (March 23): The Best Vitality & Health Protocols | Dr. Rhonda Patrick Dr. Patrick covers her comprehensive health programme — cardio and resistance training, intermittent fasting, visceral fat reduction, omega-3 sourcing, creatine for brain and muscle, and peptides including BPC-157. One of the more densely practical longevity episodes in recent memory.
🟢 ZOE Science & Nutrition
ZOE's nutrition lead Dr. Federica Amati has been raising a cautionary flag on popular longevity supplements — specifically NAD+, which she describes as inadequately regulated and under-studied for long-term use, with at least one study suggesting potential harms from long-term use. Worth noting if you're currently supplementing.
📖 ZOE Podcast | Spotify
📅 COMING UP
Targeting Longevity 2026 World Congress — Berlin, April 8–9
Livelong Women's Health Summit (featuring Mark Hyman) — San Francisco, April 17–18
XPRIZE Healthspan Top 10 finalists to receive $10M each for one-year clinical trials restoring functional capacity — announcements expected mid-2026
💡 THE WEEK IN ONE SENTENCE
The longevity field is accelerating on multiple fronts — AI-powered drug discovery is flooding into clinical trials, a landmark thymus study is rewriting what we thought we knew about immune aging, and researchers are learning to rewire inflammation rather than just suppress it.